Division of Cardiology, Keenan Research Centre in Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
Mol Ther. 2011 May;19(5):895-902. doi: 10.1038/mt.2011.18. Epub 2011 Mar 1.
Gene therapy approaches to enhance endothelial progenitor cell (EPC) homing may augment cell engraftment to ischemic tissue and lead to a greater therapeutic response. Therefore, we assessed the effects of ultrasound-mediated (UM) transfection of the chemokine stromal cell-derived factor-1 (SDF-1) on homing and engraftment of intravenously administered EPCs and the subsequent angiogenic response in chronically ischemic skeletal muscle. Bone marrow-derived EPCs were isolated from donor Fisher 344 rats, cultured and labeled in preparation for injection into recipient animals via a jugular vein. Using a model of chronic hindlimb ischemia in rats, we demonstrated that UM destruction of intravenous carrier microbubbles loaded with SDF-1 plasmid DNA resulted in targeted transfection of the vascular endothelium within ischemic muscle and greater local engraftment of EPCs. The combination of SDF-1gene therapy and EPCs lead to the greatest increase in tissue perfusion and microvascular density within ischemic muscle, compared to no treatment or either monotherapy alone. Our results demonstrate that UM transfection of SDF-1 improves EPC targeting to chronically ischemic tissue, enhancing vascular engraftment and leading to a more robust neovascularization response.
基因治疗方法可增强内皮祖细胞 (EPC) 的归巢能力,从而增加细胞在缺血组织中的植入,并产生更好的治疗效果。因此,我们评估了超声介导 (UM) 转染趋化因子基质细胞衍生因子-1 (SDF-1) 对静脉内给予的 EPC 归巢和植入以及随后慢性缺血骨骼肌中的血管生成反应的影响。从供体 Fisher 344 大鼠中分离骨髓源性 EPC,进行培养并标记,准备通过颈静脉注射到受体动物体内。我们在大鼠慢性后肢缺血模型中证明,UM 破坏载有 SDF-1 质粒 DNA 的静脉内载体微泡可导致缺血肌肉内的血管内皮的靶向转染,并增加 EPC 的局部植入。与未治疗或单独使用任何一种单药治疗相比,SDF-1 基因治疗和 EPC 的联合使用可使缺血肌肉内的组织灌注和微血管密度增加最大。我们的结果表明,UM 转染 SDF-1 可改善 EPC 对慢性缺血组织的靶向性,增强血管植入并导致更强大的新生血管化反应。